ELSEVIER

Blood 142 (2023) 635–638

The 65th ASH Annual Meeting Abstracts

ORAL ABSTRACTS

642.CHRONIC LYMPHOCYTIC LEUKEMIA: CLINICAL AND EPIDEMIOLOGICAL

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Moritz Fürstenau, MD[1], Matthias Ritgen[2], Sandra Robrecht, PhD[3], Julia Von Tresckow, MD[4], Can Zhang, PhD[5], Anke Schilhabel[6], Michael Gregor[7], Patrick Thornton[8], Philipp Bernhard Staber, MD PhD[9], Tamar Tadmor[10], Vesa Lindström[11], Gunnar Juliusson, MDPhD[12], Ann Janssens, MD[13], Mark-David Levin[14], Caspar Da Cunha-Bang, MD PhD[15], Christof Schneider, MD[16], Neta Goldschmidt[17], Elisabeth Vandenberghe, MD[18], Davide Rossi[19], Rudolf A. Benz, MD[20], Daniel Heintel[21], Christian Bjørn Poulsen[22], Ilse Christiansen, MD PhD[23], Henrik Frederiksen, MDPhD[24], Lisbeth Enggaard[25], Eduardus Posthuma[26], Djamila Issa[27,28], Hein Visser[29], Mar Bellido, MDPhD[30], Nadine Kutsch[31], Jan Dürig[32], Alexander Stehle[33], Matthias C. Voehringer, MD[34], Sebastian Böttcher[35], Clemens Schulte[36], Florian Simon, MD[37], Anna-Maria Fink, MD[3], Kirsten Fischer, MD[3], Emily Holmes[38], Karl-Anton Kreuzer[37], Monika Brüggemann, MD[39], Eugen Tausch, MD[40], Stephan Stilgenbauer, MD[40], Michael Hallek, MD[41], Arnon P. Kater, MDPhD[42], Carsten Utoft Niemann, MD PhD[43], Barbara F. Eichhorst, MD[44]

[1] Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne, Koeln, Germany
[2] Department II of Internal Medicine, University of Schleswig-Holstein, Kiel, Germany
[3] Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne, Cologne, Germany
[4] Clinic for Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
[5] German CLL Study Group, Cologne, DEU
[6] 2nd Department of Internal Medicine, University of Schleswig-Holstein, Campus Ki, Kiel, DEU
[7] Division of Hematology, Cantonal Hospital of Lucerne, Lucerne, Switzerland, Luzern, CHE
[8] Department of Haematology, Beaumont Hospital, RCSI, Cancer Trials Ireland, Dublin, Dublin, IRL
[9] Department of Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria
[10] Hematology, Bnai-Zion Medical Center, Haifa, Haifa, ISR
[11] Comprehensive Cancer Center, Department of Hematology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
[12] Lund Stem Cell Center Lund University & Hospital, Lund, Sweden
[13] University Hospitals Leuven, Leuven, Belgium
[14] Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, Dordrecht, NLD
[15] Rigshospitalet, Cohagenpen, DNK
[16] Division of CLL, Department of Internal Medicine III, University of Ulm, Ulm, Germany
[17] Department of Hematology, Hadassah Medical Center, Jerusalem, Jerusalem, ISR
[18] St. James's Hospital, Dublin, IRL
[19] Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
[20] Hematology, Muensterlingen, CHE
[21] Division of Medicine I, Klinik Ottakring, Vienna, Austria, Vienna, AUT
[22] Department of Hematology, Zealand University Hospital, Roskilde, Denmark, Roskilde, DNK
[23] Department of Hematology, Aalborg University Hospital, Aalborg, Denmark, Aalborg, DNK
[24] Department of Hematology, Odense University Hospital, Odense, Denmark
[25] Herlev Hospital, Herlev, DNK
[26] Department of Internal Medicine, Reinier The Graaf Hospital, Delft, Delft, NLD
[27] VU Medical Centre, Amsterdam, NLD
[28] Jeroen Bosch hospital, Den Bosch, Netherlands
[29] Northwest Clinics, Alkmaar, NLD

[30] Department of Hematology, University Medical Center Groningen, Groningen, NLD
[31] University of Cologne, Cologne, DEU
[32] Department for Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany, Essen, DEU
[33] Department of Hematology and Oncology, Robert-Bosch-Krankenhaus, Stuttgart, Stuttgart, Germany
[34] Robert Bosch Krankenhaus, Onkologie, Stuttgart, DEU
[35] Department of Medicine III Hematology, Oncology and Palliative Care, University Hospital, Rostock, Germany
[36] Gemeinschaftspraxis für Hämatologie und Onkologie, Dortmund, Dortmund, DEU
[37] Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne, Cologne, Cologne, DEU
[38] German CLL Study Group, University of Cologne, Cologne, Cologne, Germany
[39] Clinic for Internal Medicine II - Haematology, Oncology, University Clinic Schleswig-Holstein, Kiel, Germany
[40] Department of Internal Medicine III, Division of CLL, Ulm University, Ulm, Germany
[41] Faculty of Medicine and Cologne University Hospital, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany, Cologne, Germany
[42] Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
[43] Department of Hematology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
[44] University of Cologne, Cologne, Germany

Background

The primary endpoint analysis of the GAIA trial showed superior progression-free survival (PFS) and undetectable MRD (uMRD) rates for venetoclax-obinutuzumab (GV) and GV + ibrutinib (GIV) compared to chemoimmunotherapy (CIT) (Eichhorst et al., NEJM 2023). With additional follow-up, outcomes of the venetoclax (ven)-containing arms were compared and NGS-based MRD results were analyzed.

Methods

The phase 3 GAIA trial compared 3 different time-limited ven-based combinations against CIT in fit, treatment-naïve patients (pts) with CLL without *TP53* aberrations. Pts were randomized to CIT (FCR ≤65 years; BR >65 years), GV, GIV or ven-rituximab (RV). In addition to MRD by flow cytometry (FCM), exploratory MRD analyses were performed using the amplicon-based EuroClonality NGS assay. Reported p values have a descriptive character.

Results

In total 926 pts were randomized (CIT: 229, RV: 237, GV: 229, GIV: 231). After a median observation time of 50.7 months (interquartile range 44.6-57.9), all pts are now off study treatment. PFS continued to be superior for GV and GIV compared to CIT (GV: median not reached [NR] vs 59.4 months; hazard ratio [HR] 0.47 [97.5% CI 0.32-0.69], p<0.001; GIV: NR vs 59.4 months, HR 0.30 [97.5% CI 0.19-0.47], p<0.001, **Figure 1A**). PFS with GV and GIV was also superior compared to RV (GV: NR vs 63.2 months; HR 0.57 [97.5% CI 0.38-0.84], p=0.001; GIV: NR vs 63.2 months, HR 0.38 [97.5% CI 0.24-0.59], p<0.001). PFS between GIV and GV was not significantly different (both NR, HR 0.63 [97.5% CI 0.39-1.02], p>0.025), however, GIV was associated with longer PFS compared to GV in pts with unmutated IGHV (HR 0.58 [95% CI 0.36-0.94]) but not in pts with mutated IGHV (HR 0.87 [95% CI 0.33-2.31]). Estimated 4-year PFS rates were 62.0% (CIT), 70.1% (RV), 81.8% (GV) and 85.5% (GIV). The estimated 4-year rates for time to next treatment were 77.2% (CIT), 86.2% (RV), 90.4% (GV) and 96.0% (GIV). Of the 111 pts with subsequent therapies for CLL-type progression (excluding 12 pts with treatment for Richter's transformation as second line), 60 (54.1%) received BTKi-based therapies, 30 (27.0%) ven-based treatments, 12 (10.8%) ven + BTKi and 5 (5.4%) CIT as second-line treatments. No differences in overall survival were observed between the treatment arms (4-year OS rates, CIT 93.5%; RV 96.2%; GV 95.1%; GIV 95.0%).

In a multivariate analysis, unmutated IGHV (HR 2.86 [95% CI 1.64-5.01], p<0.001) and bulky disease (any lymph node ≥ 5 cm, HR 1.73 [95% CI 1.11-2.69], p=0.016) were independently associated with shorter PFS in the pooled GV/GIV arms.

NGS-based MRD data in PB was available for 816 pts at month 15. Of these, 22.7% (52 pts, CIT), 23.6% (56 pts, RV), 60.3% (138 pts, GV) and 66.2% (153 pts, GIV) achieved uMRD $<10^{-6}$ (uMRD6, **Figure 1B**). In all treatment arms, PFS was shorter in pts with MRD $\geq 10^{-6}$ compared to those with uMRD6 (CIT: HR 9.98 [95% CI 3.64-27.38], RV: HR 6.57 [95% CI 2.72-16.77], GV: HR 3.93 [95% CI 2.18-7.09], GIV: HR 2.10 [95% CI 1.03-4.28]). Pts who achieved uMRD below the conventional cut-off of 10^{-4} by FCM but still had low levels of detectable MRD ($\geq 10^{-6}$ & $<10^{-4}$) by NGS had shorter PFS than pts achieving uMRD6 in the pooled GV/GIV arms (HR 2.18 [95% CI 1.32-3.61], **Figure 1C**). A similar correlation was seen with CIT (HR 4.49 [95% CI 1.53-13.14]) and RV (HR 3.40 [95% CI 1.29-8.98]). In pts with uMRD6 at MO15, clinical response (partial/complete response) did not influence PFS.

Grade ≥3 infections were highest in GIV and CIT (CIT: 45 pts [20.8%], RV: 27 [11.4%], GV: 34 [14.9%], GIV: 51 [22.1%]) and cardiac disorders most frequent with GIV (CIT: 14 pts [6.5%], RV: 19 [8.0%], GV: 18 [7.9%], GIV: 41 [17.7%]). Fatal adverse events occurred in 16 (7.4%, CIT), 8 (3.4%, RV), 9 (3.9%, GV) and 11 (4.8%, GIV) pts. The rate of second primary malignancies was higher with CIT (4.19/1000 patient-months) compared to RV (2.34), GV (2.39) and GIV (2.88). When excluding non-melanoma skin cancer, the incidence rates were 2.21 (CIT) 1.21 (RV), 1.16 (GV) and 2.36 (GIV).

Conclusions

With more than 4 years of follow-up, GV and GIV show superior PFS compared to CIT and RV. Pts with unmutated IGHV have longer PFS with GIV compared to GV. A majority of pts treated with time-limited GV or GIV (60.3% and 66.2%) achieves uMRD6 at MO15. NGS-based MRD assessment identifies pts with very long PFS and appears to improve prognostication in pts with

uMRD $<10^{-4}$ by conventional FCM. Unmutated IGHV and bulky disease were independently associated with shorter PFS in pooled GV/GIV.

Disclosures Fürstenau: *BeiGene:* Research Funding; *AstraZeneca:* Research Funding; *Janssen:* Research Funding; *Roche:* Research Funding; *Abbvie:* Honoraria, Research Funding. **Ritgen:** *Janssen:* Consultancy, Honoraria; *Roche:* Consultancy, Honoraria, Research Funding; *AstraZeneca:* Consultancy, Honoraria, Other: travel support; *Abbvie:* Consultancy, Research Funding. **Von Tresckow:** *AstraZeneca:* Consultancy, Honoraria, Other, Speakers Bureau; *Roche:* Consultancy, Honoraria, Other, Speakers Bureau; *Abbvie:* Consultancy, Honoraria, Other: travel grant, Speakers Bureau; *Janssen:* Consultancy, Honoraria, Other, Speakers Bureau. **Tadmor:** *janssen,:* Research Funding; *Abbvie, ROCHE, Janssen, AstraZeneca, takeda:* Consultancy, Honoraria. **Juliusson:** *AbbVie:* Honoraria; *Jazz:* Honoraria; *Servier:* Honoraria; *Laboratoire Delbert:* Other: Research cooperation; *Novartis:* Honoraria. **Janssens:** *Novartis:* Speakers Bureau; *Eli-Lilly:* Speakers Bureau; *Amgen:* Speakers Bureau; *Gilead:* Consultancy; *Abbvie:* Consultancy; *Roche:* Consultancy; *Takeda:* Consultancy, Speakers Bureau; *Sanofi:* Speakers Bureau; *Janssen-Cilag:* Consultancy, Speakers Bureau; *Beigene:* Consultancy, Speakers Bureau; *MSD:* Consultancy; *Argenx:* Consultancy; *AstraZeneca:* Consultancy, Speakers Bureau. **Levin:** *Abbvie:* Honoraria; *Janssen:* Honoraria; *Roche:* Honoraria. **Schneider:** *Abbvie:* Honoraria, Speakers Bureau; *AstraZeneca:* Consultancy, Honoraria, Speakers Bureau; *BeiGene:* Other: travel support; *Jannsen Cilag:* Consultancy. **Rossi:** *AbbVie, AstraZeneca, Gilead, BeiGene, BMS, Janssen, Lilly, Kyte:* Honoraria, Research Funding. **Frederiksen:** *Novartis:* Research Funding; *Sanofi:* Research Funding; *Alexion:* Research Funding; *Gilead:* Research Funding; *AbbVie:* Research Funding; *Janssen Pharmaceuticals:* Research Funding. **Kutsch:** *Celgene:* Other: travel support; *Gilead:* Honoraria, Other: travel support, Research Funding; *AbbVie:* Honoraria, Other: travel support; *Roche:* Honoraria; *BMS:* Honoraria; *AstraZeneca:* Honoraria, Research Funding; *Janssen:* Other: travel support. **Dürig:** *Roche:* Consultancy, Honoraria, Other: travel support; *Sanofi:* Consultancy, Honoraria, Other: travel support; *Beigene:* Consultancy, Honoraria, Other: travel support; *Celgene:* Consultancy, Honoraria, Other: travel support; *Janssen:* Consultancy, Honoraria, Other: travel support; *AstraZeneca:* Consultancy, Honoraria, Other: travel support; *Amgen:* Consultancy, Honoraria, Other: travel support; *Abbvie:* Consultancy, Honoraria, Other: travel support. **Böttcher:** *AstraZeneca:* Honoraria, Speakers Bureau; *Sanofi:* Honoraria, Speakers Bureau; *Janssen:* Honoraria, Research Funding, Speakers Bureau; *Abbvie:* Honoraria, Speakers Bureau; *Roche:* Honoraria, Speakers Bureau. **Simon:** *AstraZeneca:* Research Funding; *Lilly Pharma:* Other: Travel support. **Fink:** *Abbvie:* Other: travel support; *AstraZeneca:* Consultancy, Honoraria, Research Funding. **Fischer:** *Roche:* Honoraria, Other: Travel Support; *AstraZeneca:* Consultancy; *Abbvie:* Honoraria, Other: TRavel support. **Kreuzer:** *Abbvie:* Consultancy, Research Funding, Speakers Bureau; *Janssen:* Consultancy, Research Funding, Speakers Bureau; *Roche:* Consultancy, Research Funding, Speakers Bureau. **Brüggemann:** *Incyte:* Membership on an entity's Board of Directors or advisory committees; *Amgen:* Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; *Regeneron:* Research Funding; *Pfizer:* Speakers Bureau; *Affimed:* Research Funding; *BD:* Speakers Bureau; *Janssen:* Speakers Bureau. **Tausch:** *Janssen-Cilag:* Consultancy, Honoraria, Other: travel support, Speakers Bureau; *Abbvie:* Consultancy, Honoraria, Other: Travel Support, Research Funding, Speakers Bureau; *Roche:* Consultancy, Honoraria, Research Funding, Speakers Bureau; *AstraZeneca:* Consultancy, Honoraria, Other: travel support, Speakers Bureau; *BeiGene:* Consultancy, Other: Travel support, Speakers Bureau. **Stilgenbauer:** *Amgen:* Consultancy, Honoraria, Other: travel support, Research Funding; *Abbvie:* Consultancy, Honoraria, Other: travel support, Research Funding; *Celgene:* Consultancy, Honoraria, Other: travel support, Research Funding; *Gilead:* Consultancy, Honoraria, Other: travel support, Research Funding; *GSK:* Consultancy, Honoraria, Other: travel support, Research Funding; *Roche:* Consultancy, Honoraria, Other: travel support, Research Funding; *Janssen:* Consultancy, Honoraria, Other: travel support, Research Funding; *Novartis:* Consultancy, Honoraria, Other: travel support, Research Funding; *Sunesis:* Consultancy, Honoraria, Other: travel support, Research Funding; *AstraZeneca:* Consultancy, Honoraria, Other: travel support, Research Funding. **Hallek:** *AstraZeneca:* Consultancy, Honoraria, Research Funding; *Janssen:* Consultancy, Honoraria, Research Funding; *Gilead:* Consultancy, Honoraria, Research Funding; *Abbvie:* Consultancy, Honoraria, Research Funding; *BeiGene:* Consultancy, Honoraria, Research Funding; *Roche:* Consultancy, Honoraria, Research Funding. **Kater:** *LAVA:* Consultancy, Honoraria, Research Funding; *Astra Zeneca:* Consultancy, Honoraria, Research Funding; *BMS:* Consultancy, Honoraria, Research Funding; *Genentech, Inc.:* Consultancy, Honoraria, Research Funding; *Janssen:* Consultancy, Honoraria, Research Funding; *Abbvie:* Consultancy, Honoraria, Research Funding. **Niemann:** *Carsten Niemann has received research funding and/or consultancy fees from AstraZeneca, Janssen, AbbVie, Beigene, Genmab, CSL Behring, Octapharma, Takeda, and Novo Nordisk Foundation.:* Consultancy, Research Funding. **Eichhorst:** *AstraZeneca:* Consultancy, Honoraria, Research Funding, Speakers Bureau; *BeiGene:* Consultancy, Honoraria, Research Funding, Speakers Bureau; *Gilead:* Consultancy, Research Funding; *Janssen:* Consultancy, Research Funding, Speakers Bureau; *Lilly:* Consultancy, Speakers Bureau; *MSD:* Consultancy, Honoraria, Speakers Bureau; *F. Hoffmann-La Roche Ltd:* Honoraria, Research Funding, Speakers Bureau; *Abbvie:* Consultancy, Honoraria, Research Funding, Speakers Bureau.

OffLabel Disclosure: The triple combination of venetoclax, ibrutinib and obinutuzumab is not approved for the treatment of CLL

Figure 1



Figure 1

https://doi.org/10.1182/blood-2023-173709